News | Ablation Systems | November 14, 2016

Catheter Ablations Reduce Long-Term Stroke Risk in Patients with Prior Stroke History

Intermountain study finds stroke rates similar between atrial fibrillation patients treated with ablation and patients with no history of AFib

catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association

November 14, 2016 — Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of a recurrent stroke by 50 percent, according to new research from the Intermountain Medical Center Heart Institute.

Atrial fibrillation is an abnormal heart rhythm caused by rogue electrical currents in the heart. The arrhythmia allows blood to pool and clot in the heart. When the clot breaks loose, it travels to the brain and causes a stroke.

When medications are not successful in treating the arrhythmia, catheter ablations are used to create scar tissue in the upper left atrium of the heart that prevents rapid, chaotic electric currents, often from the pulmonary veins, from causing the abnormal rhythm.

“One of the most devastating complications of atrial fibrillation is a stroke and its prevention is the treatment cornerstone of the abnormal heart rhythm,” said Jared Bunch, M.D., lead author of the study and director of electrophysiology at the Intermountain Medical Center Heart Institute in Salt Lake City. “Patients that have a prior history of stroke have a much greater risk of recurrent strokes. Our new research shows the more successful we are in treating the abnormal rhythm through the process required with catheter ablation, the better chance we have of lowering a patient’s long-term risk of stroke.”

Results of the study were presented during the American Heart Association’s Scientific Sessions, Nov. 12-16 in New Orleans.

The Intermountain study compared a group of 140 patients, who had a prior history of stroke and underwent their first catheter ablation, to two other patient groups, both of which also had a prior history of stroke, including 416 atrial fibrillation patients who did not receive a catheter ablation, and 416 stroke patients who did not have atrial fibrillation.

The patients were followed for five years and observed for recurrent outcomes of stroke, heart failure and death.

The five-year risk of patients having another stroke was decreased in the patients who had a catheter ablation to treat atrial fibrillation, compared to the group that had no catheter ablation to treat their abnormal heart rhythm. The stroke rates of atrial fibrillation patients that underwent an ablation procedure were similar to patients with no history of atrial fibrillation.

“One of the most important findings of this study was that stroke rates in patients that underwent an ablation were similar to patients with no history of atrial fibrillation. This suggests that our management approach can alter some of the negative effects and natural history of atrial fibrillation. As physicians, we spend a lot of our time and energy trying to prevent stroke. This study helps us understand better how our management approaches can alter stroke risk,” said Bunch. “Our research shows that more aggressive treatment of atrial fibrillation by using catheter ablations will reduce the chances a person will have a life-threatening stroke.”

Other members of the Intermountain Medical Center Heart Institute team include Heidi T. May, Ph.D.; Tami L. Bair, RN; Victoria Jacobs, Ph.D.; Brian G. Crandall, M.D.; Michael Cutler, M.D.; Jeffrey S. Osborn, M.D.; Charles Mallender, M.D.; John D. Day, M.D.; and Peter Weiss, M.D.

For more information: www.scientificsessions.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init